CRC
PTCT icon

Curi RMB Capital’s PTC Therapeutics PTCT Stock Holding History

Curi RMB Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,858
Closed -$243K – 525
2023
Q3 		$243K Hold
10,858
– – 0.01% 453
2023
Q2 		$442K Buy
+10,858
New +$531K 0.01% 393
2019
Q3 		– Sell
-31,621
Closed -$1.42M – 775
2019
Q2 		$1.42M Buy
+31,621
New +$1.25M 0.04% 368

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Curi RMB Capital's PTCT Position: Q4 2023 in Review

Curi RMB Capital sold out of PTC Therapeutics (PTCT) in Q4 2023, closing a stake of 10,858 shares — an estimated $243K sold.

Curi RMB Capital first reported a position in PTCT in Q2 2019 and held it in 3 quarters. The position peaked at $1.42M in Q2 2019. 172 funds tracked by Wall St. Rank hold PTCT as of Q4 2023.

  • Curi RMB Capital reported no remaining PTC Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Curi RMB Capital sold 10,858 PTC Therapeutics shares in Q4 2023, an estimated $243K.
  • Curi RMB Capital first reported a position in PTC Therapeutics in Q2 2019 and held it in 3 quarters.
  • Curi RMB Capital's PTC Therapeutics position peaked at $1.42M in Q2 2019.
  • 172 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2023.

Based on Curi RMB Capital's 13F filing for Q4 2023, filed 14 Feb 2024.